Biotech & Medicine
186 articles RSS
Intellia's In Vivo CRISPR Therapy Cuts Hereditary Angioedema Attacks 87% in Phase 3 HAELO Trial Published in NEJM
Lonvoguran ziclumeran met its primary endpoint with an 87% reduction in monthly attacks, the first Phase 3 win for an in vivo CRISPR therapy.
FDA Approves Wockhardt's Zaynich, a Cefepime-Zidebactam Antibiotic for Drug-Resistant Gram-Negative UTIs
Wockhardt's intravenous cefepime-zidebactam combination won U.S. FDA approval for complicated urinary tract infections after a phase 3 trial showed superiority over meropenem.
Ionis's Zilganersen Becomes First Drug to Show Disease-Modifying Effect in Alexander Disease as FDA Sets September Decision
An antisense drug stabilized walking speed in a 54-patient pivotal trial; the FDA accepted Ionis's NDA for Priority Review with a target action date of September 22, 2026.
Takeda's Zasocitinib Beats Deucravacitinib Head-to-Head in Phase 3 Psoriasis Trial, More Than Doubling Complete Skin Clearance
In the LATITUDE Atlas trial, more than 35% of patients on Takeda's oral TYK2 inhibitor reached completely clear skin at week 16 — more than 2.5 times the rate seen with Bristol Myers Squibb's deucravacitinib.
ETH Zurich Pins a New Alzheimer's Driver on Clumps of an Inactive Enzyme, and an Experimental Compound That Breaks Them Up
ETH Zurich researchers report that aggregates of inactivated GRK2 choke mitochondria and fuel amyloid beta, and that an experimental molecule, compound 10, slowed nerve cell death in mice.
SENOMAC's Mature Survival Data at ASCO 2026 Confirms Many Breast Cancer Patients Can Safely Skip Axillary Dissection
Five-year overall survival was non-inferior when surgeons omitted completion axillary dissection, while severe arm problems fell from 12.6% to 3.6%.
During Sleep the Visual Cortex Inverts Its Response to Light Even as the Thalamus Keeps Relaying It, a Boston University EEG-fMRI Study Finds
A Nature Communications study used simultaneous EEG-fMRI to show that early sleep suppresses light responses in the visual cortex while the thalamus stays intact.
Manikomycin, a Natural Antibiotic That Hits a Never-Targeted Ribosome Site, Kills Drug-Resistant Bacteria in Nature Study
McMaster-led researchers report in Nature a depsipeptide antibiotic that blocks the bacterial ribosome's E-site, a target no existing drug uses.
Viridian's Veligrotug Nears a June 30 FDA Decision for Thyroid Eye Disease, Pitching a Five-Infusion Course Against Tepezza
An FDA decision on Viridian's IGF-1R antibody veligrotug is due June 30, 2026, after Phase 3 trials hit their endpoints in both active and chronic thyroid eye disease.
Atacicept Cuts Proteinuria 46% in Phase 3 ORIGIN Trial for IgA Nephropathy, Setting Up a July FDA Decision
Vera Therapeutics' dual BAFF/APRIL inhibitor reduced proteinuria 45.7% at week 36 in the NEJM-published ORIGIN 3 trial, with an FDA accelerated-approval decision due July 7.
Eli Lilly's Retatrutide Cuts Body Weight 28.3% in Phase 3 TRIUMPH-1 as Triple-Agonist Data Land at ADA 2026
Eli Lilly presented phase 3 results for retatrutide at ADA 2026 on June 6, showing 28.3% mean weight loss at 80 weeks in obesity and a companion diabetes trial published in The Lancet.
Ivonescimab Beats a PD-1 Standard in First-Line Squamous Lung Cancer at ASCO, the First China-Originated Drug to Reach the Society's Plenary
HARMONi-6 showed Akeso's PD-1/VEGF bispecific cut the risk of death by 34% versus tislelizumab plus chemotherapy, and reached the ASCO plenary for the first time for a China-originated cancer drug.